Please assess the completion status of the following clinical trial:

Trial Title: A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~\[For all parts\]~1. Japanese patients diagnosed with AML by the 4th edition of WHO criteria.~2. Patients aged between 20 and 64 at acquisition of informed consent.~3. Have received an adequate explanation of the objectives/contents of the clinical study, anticipated therapeutic effects/pharmacology, and risks to his/her understanding, and voluntarily provide written informed consent to participation in the clinical study.~4. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2 at entry.~5. Have a left ventricular ejection fraction (LVEF) ≥ 50% determined by echocardiography or multigated acquisition (MUGA) scan within 14 days prior to entry.~6. Have an arterial oxygen saturation (SpO2) ≥ 90% within 14 days prior to entry.~7. The laboratory test within 14 days prior to entry (for multiple tests, the most recent before the entry) meet the following criteria for major organ function.~   1. Serum creatinine ≤ 1.5 x the upper limit of normal (ULN) of the institutional reference standard~  2. AST and ALT ≤ 2 x ULN of the institutional reference standard~  3. Total bilirubin ≤ 2.0 mg/dL~8. Female patients of childbearing potential must have negative pregnancy test results at entry.~9. Female patients or patients with partners of childbearing potential must agree to use an appropriate method of contraception for a period between acquisition of informed consent and 6 months (180 days) after the final dose so that patients or female partners would not become pregnant.~   \[ACM regimen part\] In addition to the inclusion criteria for all parts, patients must meet the following criterion.~10. AML patients who could not attain remission after 1 or 2 cycles of potent chemotherapy with anthracycline, cytarabine, and etoposide, or potent chemotherapy with anthracycline and cytarabine. Or patients with 1st or 2nd recurrent AML after complete remission following initial therapy.~    \[A+7+3 regimen part\] In addition to the inclusion criteria for all parts, patients must meet the following criterion~11. Treatment naive AML patients.~Exclusion Criteria:~\[For all parts\]~1. Diagnosed with acute promyelocytic leukemia (APL) (FAB classification: M3).~2. Received a transplantation such as hematopoietic stem cell transplant.~3. Have active central nervous system (CNS) leukemia.~4. Complicated by ≥ Grade 3 infection as specified in Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03).~5. HIV antibody, HBs antigen, or HCV antibody tested positive within 90 days prior to entry.~6. Have New York Heart Association (NYHA) cardiac function classification III or IV heart disease or a history, ≥ Grade 3 arrhythmia, angina pectoris or abnormal electrocardiogram (ECG) findings as specified in CTCAE v4.03 or a history of these above.~7. Have a disease that may interfere with the study treatment, such as interstitial pneumonia, pulmonary fibrosis, or active tuberculosis.~8. Complicated by uncontrolled disseminated intravascular coagulation.~9. Have other active malignancies (synchronous multiple malignancies and metachronous multiple malignancies with a disease-free interval not more than 5 years. However, carcinoma in situ that is determined to be cured by local treatment or lesions equivalent to mucosal carcinoma are not included in active multiple malignancies.)~10. Have an uncontrolled complication.~11. Complicated by mental deficits or have a history of mental deficits. However, patients who are able to comply with the study protocol can be included at the discretion of a physician.~12. Complicated by varicella.~13. Received any previous treatment with DSP-2033 or other CDK inhibitors.~14. Received any investigational product or post-marketing clinical study drug within 3 months (90 days) prior to entry.~15. Pregnant or lactating women\*)~    \*) If a lactating woman agrees to discontinue breast feeding between acquisition of informed consent and 6 months (180 days) after the final dose, she could be included in the study.~16. Patients who are determined to be inappropriate for participation in this study by the investigator or subinvestigator.~    \[ACM regimen part\] In addition to the exclusion criteria cfor all parts, patients who meet any one of the following criteria 17 to 21 will be excluded from the ACM regimen part.~17. Have the cumulative total exposure of anthracycline, daunorubicin-equivalent dose, exceeds 360 mg/m2 (body surface area) at entry.~18. Received other leukemia treatment within 21 days prior to entry.~19. Have a history of radiation therapy on the mediastinum.~20. Have sustained ≥ Grade 2 adverse drug reaction (except alopecia) as specified in CTCAE v4.03, which developed by the previous treatment.~21. Have a history of hypersensitivity against any one of cytarabine, mitoxantrone, or contained excipients.~    \[A+7+3 regimen part\] In addition to the exclusion criteria for all parts, patients who meet any one of the following criteria 22 to 23 will be excluded from the A+7+3 regimen part.~22. Have the cumulative total exposure of anthracycline, daunorubicin-equivalent dose, exceeds 100 mg/m2 (body surface area) at entry.~23. Have a history of hypersensitivity against any one of cytarabine, daunorubicin, or contained excipients.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- ACM regimen (Type: EXPERIMENTAL): ACM regimen is for Japanese patients with relapsed or refractory AML.
- A+7+3 regimen (Type: EXPERIMENTAL): A+7+3 regimen is for Japanese newly diagnosed AML patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).